NHWD-870, a BRD4 inhibitor that has been reported to be more potent than three major clinical-stage BET inhibitors, BMS-986158, OTX-015, and GSK-525762, blocks the proliferation of TAMs in subcutaneously implanted H526 and A2780 tumors, at least partially by reducing the expression and secretion of CSF1 by cancer cells [250]. Here, CSF1 is linked to cancer.